DHX9 and pachyonychia congenita: Noteworthy, inhibitors of the interaction between DHX9 and other transcription factors, such as members of the ETS family, have been developed and have shown promising preclinical results in various tumors [16–18, 45, 46], including PC [19, 20, 47, 48].